Kenji Hibi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Kenji Hibi has a total of 40 co-authors. Here are the top co-authors by number of shared publications:
- Akimasa Nakao
Department of Surgery, Nagoya Central Hospital, Nagoya, Japan
15 shared publications - Katsuki Ito
Department of Surgery II, School of Medicine, Nagoya University, Nagoya, Japan
12 shared publications Yasuhiro Kodera
10 shared publications- Seiji Akiyama
Department of Surgery II, Nagoya University School of Medicine, Nagoya, Japan
9 shared publications - Michitaka Fujiwara
Nagoya University Graduate School of Medicine, Nagoya, Japan
8 shared publications - Masahiko Koike
Nagoya University Graduate School of Medicine
7 shared publications
Latest Publications
- 18 September 2008
- Vol. 55 (85) , 1480-3
PAI-1 expression levels in gastric cancers are closely correlated to those in corresponding normal tissues.
To investigate the mechanism of PAI-1 overexpression in gastric cancers, the PAI-1 expression levels in gastric cancers were compared to those in the corresponding normal tissues. A quantitative RT-PCR for PAI-1 gene was performed in gastric cancers and corresponding normal tissues, and evaluated the association between the PAI-1 expression levels in gastric cancers and those in corresponding normal tissues. There was a significant correlation between gastric cancer and corresponding normal PAI-1 expressions with a Spearman's rank correlation coefficient of 0.74 (p < 0.0001). PAI-1 expression levels in corresponding normal tissues increased significantly with tumor stage [stage I, -8.04 +/- 0.72; stage II, -7.71 +/- 0.61: stage III, -6.81 +/- 0.51; stage IV, -4.95 +/- 0.20 (p = 0.0022)). Previous studies found that PAI-1 overexpression was significantly associated with malignancy of gastric cancers. Taken together, PAI-1 overexpression in gastric cancers might be originated from higher PAI-1 expression in corresponding normal tissues and result in a malignant phenotype of these cancers.
- 18 September 2008
- Vol. 55 (85) , 1480-3
PAI-1 expression levels in gastric cancers are closely correlated to those in corresponding normal tissues.
To investigate the mechanism of PAI-1 overexpression in gastric cancers, the PAI-1 expression levels in gastric cancers were compared to those in the corresponding normal tissues. A quantitative RT-PCR for PAI-1 gene was performed in gastric cancers and corresponding normal tissues, and evaluated the association between the PAI-1 expression levels in gastric cancers and those in corresponding normal tissues. There was a significant correlation between gastric cancer and corresponding normal PAI-1 expressions with a Spearman's rank correlation coefficient of 0.74 (p < 0.0001). PAI-1 expression levels in corresponding normal tissues increased significantly with tumor stage [stage I, -8.04 +/- 0.72; stage II, -7.71 +/- 0.61: stage III, -6.81 +/- 0.51; stage IV, -4.95 +/- 0.20 (p = 0.0022)). Previous studies found that PAI-1 overexpression was significantly associated with malignancy of gastric cancers. Taken together, PAI-1 overexpression in gastric cancers might be originated from higher PAI-1 expression in corresponding normal tissues and result in a malignant phenotype of these cancers.
- 1 November 2007
- Vol. 27, 3367-70
P16 methylation in serum as a potential marker for the malignancy of colorectal carcinoma.
The aim of the present study was to determine if p16 methylation in the serum can serve as a candidate marker for the malignancy of colorectal carcinoma, real-time quantitative methylation-specific PCR (RTQ-MSP) was performed for p16 methylation in serum and the relationship between p16 methylation levels and clinicopathological findings of colorectal carcinoma was evaluated. The p16 methylation score significantly increased with tumor stage (stage I=0.94+/-0.47, stage 11=2.33+/-0.90, stage 111=8.49+/-2.37, stage IV=10.03+/-4.30) (p=0.021; ANOVA). The p16 methylation score was significantly higher in patients with lymph node metastasis (p=0.001) and tumor invasion to the veins (p=0.020). The cumulative survival of patient groups according to the p16 methylation score (more or less than 1) was examined. Interestingly, the group with a high p16 methylation score showed significantly worse survival rates than the group with a low p16 expression score (p= 0.006). The p16 methylation score might serve as a new parameter for the prognosis of colorectal carcinoma. Moreover, p16 methylation was found in the serum of patients in all clinical stages, suggesting that early colorectal carcinoma could be detected using the RTQ-MSP method.
- 1 November 2007
- Vol. 27, 3367-70
P16 methylation in serum as a potential marker for the malignancy of colorectal carcinoma.
The aim of the present study was to determine if p16 methylation in the serum can serve as a candidate marker for the malignancy of colorectal carcinoma, real-time quantitative methylation-specific PCR (RTQ-MSP) was performed for p16 methylation in serum and the relationship between p16 methylation levels and clinicopathological findings of colorectal carcinoma was evaluated. The p16 methylation score significantly increased with tumor stage (stage I=0.94+/-0.47, stage 11=2.33+/-0.90, stage 111=8.49+/-2.37, stage IV=10.03+/-4.30) (p=0.021; ANOVA). The p16 methylation score was significantly higher in patients with lymph node metastasis (p=0.001) and tumor invasion to the veins (p=0.020). The cumulative survival of patient groups according to the p16 methylation score (more or less than 1) was examined. Interestingly, the group with a high p16 methylation score showed significantly worse survival rates than the group with a low p16 expression score (p= 0.006). The p16 methylation score might serve as a new parameter for the prognosis of colorectal carcinoma. Moreover, p16 methylation was found in the serum of patients in all clinical stages, suggesting that early colorectal carcinoma could be detected using the RTQ-MSP method.
- 29 June 2007
- Vol. 27, 1459-63
A highly sensitive method for the detection of p16 methylation in the serum of colorectal cancer patients.
For the purpose of early detection of carcinomas, detection of p16 hypermethylation by methylation-specific polymerase chain reaction (MSP) in the serum of many kinds of malignancies has been introduced. An attempt to increase the sensitivity of this assay is reported for colorectal cancer. DNA samples were subjected to limiting dilution before being divided into ten smaller samples. Subsequently, hemi-nested MSP was performed on those ten samples. The limiting dilution-MSP (LD-MSP) provided a 10-fold increase in sensitivity of the detection of methylated DNA compared with conventional MSP. Of 44 colorectal cancer patients, 30 (68%) exhibited abnormal promoter methylation of p16 in their serum DNA by LD-MSP, while 13 (30%) exhibited it by conventional MSP. As a control, the serum DNA of 50 patients with colorectal carcinomas whose corresponding tumor DNA had no methylation in the p16 promoter was screened for aberrant methylation. No methylation was found in the serum DNA of this control group by LD-MSP or conventional MSP. The high sensitivity of LD-MSP makes it possible to detect smaller amounts of tumor DNA in the serum than conventional MSP. This technique also has great specificity and no abnormal methylation in serum has yet been observed if the corresponding tumor does not exhibit methylation. This observation supports the idea that LD-MSP could be applied in clinical use for the detection of tumor DNA in serum.
- 29 June 2007
- Vol. 27, 1459-63
A highly sensitive method for the detection of p16 methylation in the serum of colorectal cancer patients.
For the purpose of early detection of carcinomas, detection of p16 hypermethylation by methylation-specific polymerase chain reaction (MSP) in the serum of many kinds of malignancies has been introduced. An attempt to increase the sensitivity of this assay is reported for colorectal cancer. DNA samples were subjected to limiting dilution before being divided into ten smaller samples. Subsequently, hemi-nested MSP was performed on those ten samples. The limiting dilution-MSP (LD-MSP) provided a 10-fold increase in sensitivity of the detection of methylated DNA compared with conventional MSP. Of 44 colorectal cancer patients, 30 (68%) exhibited abnormal promoter methylation of p16 in their serum DNA by LD-MSP, while 13 (30%) exhibited it by conventional MSP. As a control, the serum DNA of 50 patients with colorectal carcinomas whose corresponding tumor DNA had no methylation in the p16 promoter was screened for aberrant methylation. No methylation was found in the serum DNA of this control group by LD-MSP or conventional MSP. The high sensitivity of LD-MSP makes it possible to detect smaller amounts of tumor DNA in the serum than conventional MSP. This technique also has great specificity and no abnormal methylation in serum has yet been observed if the corresponding tumor does not exhibit methylation. This observation supports the idea that LD-MSP could be applied in clinical use for the detection of tumor DNA in serum.
- 1 May 2007
- Vol. 27 (2) , 851-6
Gene expression profile of 5-fluorouracil metabolic enzymes in primary colorectal cancer: potential as predictive parameters for response to fluorouracil-based chemotherapy.
Thymidylate synthase (TS), dihydropyrimidine dehydrogenase (DPD), thymidine phosphorylase (TP) and orotate phosphoribosyltransferase (OPRT) have been reported to be predictive parameters for the efficacy of fluoropyrimidine-based chemotherapy. Therapy guided by chemotherapy sensitivity and resistance assays may lead to rational treatment decisions. mRNA expression of TS, DPD, TP, and OPRT were quantified by reverse-transcriptase polymerase chain reaction (RT-PCR) after harvesting from paraffin embedded specimens through microdissection. In vitro chemosensitivity testing by histoculture drug response assay (HDRA) was performed with fresh specimens of the primary tumor from 49 patients with colorectal cancer. Correlations between the results of a chemosensitivity test (the T/C ratio; the percentage of optical density of a tumor treated with anticancer drugs in relation to the optical density of the tumor cultured in RPMI 1640 medium only) and the gene expression were assessed. The gene expression of TS, TP, and OPRT had no correlation with clinicopathological factors, survival, and T/C ratio. The DPD mRNA levels (0.295 vs. 0.381, p = 0.2460) and OPRT/DPD ratio (5.535 vs. 4.394. p = 0.226) had a weak correlation with the T/C ratio. Of the eleven patients who were actually treated with chemotherapy, the responders had higher OPRT/DPD ratios (8.065 vs. 4.081, p = 0.090). The DPD mRNA level and OPRT/DPD ratio evaluated from paraffin embedded specimens are candidates for further evaluation as predictors of response against 5-fluorouracil-based chemotherapy in colorectal cancer.
- 1 May 2007
- Vol. 27 (2) , 851-6
Gene expression profile of 5-fluorouracil metabolic enzymes in primary colorectal cancer: potential as predictive parameters for response to fluorouracil-based chemotherapy.
Thymidylate synthase (TS), dihydropyrimidine dehydrogenase (DPD), thymidine phosphorylase (TP) and orotate phosphoribosyltransferase (OPRT) have been reported to be predictive parameters for the efficacy of fluoropyrimidine-based chemotherapy. Therapy guided by chemotherapy sensitivity and resistance assays may lead to rational treatment decisions. mRNA expression of TS, DPD, TP, and OPRT were quantified by reverse-transcriptase polymerase chain reaction (RT-PCR) after harvesting from paraffin embedded specimens through microdissection. In vitro chemosensitivity testing by histoculture drug response assay (HDRA) was performed with fresh specimens of the primary tumor from 49 patients with colorectal cancer. Correlations between the results of a chemosensitivity test (the T/C ratio; the percentage of optical density of a tumor treated with anticancer drugs in relation to the optical density of the tumor cultured in RPMI 1640 medium only) and the gene expression were assessed. The gene expression of TS, TP, and OPRT had no correlation with clinicopathological factors, survival, and T/C ratio. The DPD mRNA levels (0.295 vs. 0.381, p = 0.2460) and OPRT/DPD ratio (5.535 vs. 4.394. p = 0.226) had a weak correlation with the T/C ratio. Of the eleven patients who were actually treated with chemotherapy, the responders had higher OPRT/DPD ratios (8.065 vs. 4.081, p = 0.090). The DPD mRNA level and OPRT/DPD ratio evaluated from paraffin embedded specimens are candidates for further evaluation as predictors of response against 5-fluorouracil-based chemotherapy in colorectal cancer.
- 5 January 2007
- Vol. 26, 4267-70
Aberrant methylation of the CHFR gene is frequently detected in non-invasive colorectal cancer.
Aberrant methylation of the CHFR gene associated with gene silencing has been reported in several primary tumors. In order to define the role of CHFR in the tumorigenic pathway of the colorectum, the methylation of CHFR was examined in tumors from colorectal cancer patients. Ninety-eight colorectal cancer patients were examined using a methylation-specific PCR (MSP) for CHFR CpG island in primary tumors. An aberrant methylation of the CHFR gene was detected in 25 out of 98 (26%) primary colorectal cancers. No methylation was detected in the corresponding normal tissue specimens. This finding suggested that an aberrant methylation of the CHFR gene occurs frequently in colorectal cancers. After a methylation analysis of all samples, the clinicopathological data were correlated with these results. A significant difference was found in the tumor (p = 0.035), thus, indicating that in early colorectal cancer the CHFR gene was more frequently methylated than in advanced cases. These findings suggest that CHFR might act as a tumor suppressor in at least some colorectal cancers and that CHFR methylation might, therefore, be a particular phenomenon of early colorectal cancer.
- 5 January 2007
- Vol. 26, 4267-70
Aberrant methylation of the CHFR gene is frequently detected in non-invasive colorectal cancer.
Aberrant methylation of the CHFR gene associated with gene silencing has been reported in several primary tumors. In order to define the role of CHFR in the tumorigenic pathway of the colorectum, the methylation of CHFR was examined in tumors from colorectal cancer patients. Ninety-eight colorectal cancer patients were examined using a methylation-specific PCR (MSP) for CHFR CpG island in primary tumors. An aberrant methylation of the CHFR gene was detected in 25 out of 98 (26%) primary colorectal cancers. No methylation was detected in the corresponding normal tissue specimens. This finding suggested that an aberrant methylation of the CHFR gene occurs frequently in colorectal cancers. After a methylation analysis of all samples, the clinicopathological data were correlated with these results. A significant difference was found in the tumor (p = 0.035), thus, indicating that in early colorectal cancer the CHFR gene was more frequently methylated than in advanced cases. These findings suggest that CHFR might act as a tumor suppressor in at least some colorectal cancers and that CHFR methylation might, therefore, be a particular phenomenon of early colorectal cancer.
- 11 November 2006
- Vol. 26, 3333-5
Aberrant methylation is frequently observed in advanced esophageal squamous cell carcinoma.
The combined methylation status of the p16, helicase-like transcription factor (HLTF) and T-cadherin, H-cadherin (CDH13) genes in 35 resected primary esophageal squamous cell carcinoma (ESCC) was examined using methylation-specific PCR. To examine whether the methylation status could be a marker for the malignancy of ESCC, the methylation status was correlated with the clinicopathological features of the affected patients. Aberrant methylation of the p16, HLTF and CDH13 genes was detected in 28 (80%), one (3%) and five (14%) out of 35 ESCC specimens, respectively. ESCC with methylation-positive genes showed a trend towards larger tumor size and deeper invasion (p = 0.139 and p = 0.0664, respectively). Thus, the methylation of the p16, HLTF and CDH13 genes is a high malignancy factor in ESCC.
- 11 November 2006
- Vol. 26, 3333-5
Aberrant methylation is frequently observed in advanced esophageal squamous cell carcinoma.
The combined methylation status of the p16, helicase-like transcription factor (HLTF) and T-cadherin, H-cadherin (CDH13) genes in 35 resected primary esophageal squamous cell carcinoma (ESCC) was examined using methylation-specific PCR. To examine whether the methylation status could be a marker for the malignancy of ESCC, the methylation status was correlated with the clinicopathological features of the affected patients. Aberrant methylation of the p16, HLTF and CDH13 genes was detected in 28 (80%), one (3%) and five (14%) out of 35 ESCC specimens, respectively. ESCC with methylation-positive genes showed a trend towards larger tumor size and deeper invasion (p = 0.139 and p = 0.0664, respectively). Thus, the methylation of the p16, HLTF and CDH13 genes is a high malignancy factor in ESCC.
- 26 September 2006
- Vol. 53 (70) , 648-50
Laparoscopy-assisted total gastrectomy for a case of MALT lymphoma: a case report.
A case of laparoscopy-assisted total gastrectomy with regional lymph node dissection for MALT (mucosa-associated lymphoid tissue) lymphoma is reported. The patient was a 45-year-old male with MALT lymphoma. Eradication of Helicobacter pylori as the initial therapy had failed to halt progression of the tumor. Considering certainty of the second therapy, he was transferred to surgical treatment. Total gastrectomy was required and this was performed by the laparoscopy-assisted approach. The postoperative course was satisfactory and the patient has been disease-free for 5 years after the operation. Laparoscopic operation could be a useful option in the second-line treatment for MALT lymphoma after failure to eradicate H. pylori.
- 26 September 2006
- Vol. 53 (70) , 648-50
Laparoscopy-assisted total gastrectomy for a case of MALT lymphoma: a case report.
A case of laparoscopy-assisted total gastrectomy with regional lymph node dissection for MALT (mucosa-associated lymphoid tissue) lymphoma is reported. The patient was a 45-year-old male with MALT lymphoma. Eradication of Helicobacter pylori as the initial therapy had failed to halt progression of the tumor. Considering certainty of the second therapy, he was transferred to surgical treatment. Total gastrectomy was required and this was performed by the laparoscopy-assisted approach. The postoperative course was satisfactory and the patient has been disease-free for 5 years after the operation. Laparoscopic operation could be a useful option in the second-line treatment for MALT lymphoma after failure to eradicate H. pylori.
- 11 July 2006
- Vol. 26, 1791-5
Aberrant methylation of the CHFR gene in digestive tract cancer.
Recently, aberrant methylation of the CHFR gene associated with gene silencing has been reported in several cancers. The methylation status of the CHFR gene was examined in primary esophageal and gastric carcinomas. The methylation status of the CHFR promoter region and mRNA expression in cancer cell lines were examined first. The methylation status of the CHFR gene in 38 esophageal and 53 gastric cancers was subsequently examined and the correlation between CHFR methylation and the clinicopathological findings was investigated. Aberrant methylation of the CHFR gene was detected in 9 out of 38 (24%) primary esophageal and 16 out of 53 (30%) primary gastric cancers. After methylation analysis of all the samples, the clinicopathological data were correlated with these results. There was a significant difference according to gender (p = 0.0404), indicating that female esophageal cancers were more frequently methylated than male. On the other hand, abnormal methylation was found in esophageal and gastric cancer patients at all clinical stages. Aberrant methylation of the CHFR gene was frequently shown in esophageal and gastric cancers. In addition, abnormal methylation was found in these cancer patients at all clinical stages, suggesting that this cancer could be methylated at an early stage.
- 11 July 2006
- Vol. 26, 1791-5
Aberrant methylation of the CHFR gene in digestive tract cancer.
Recently, aberrant methylation of the CHFR gene associated with gene silencing has been reported in several cancers. The methylation status of the CHFR gene was examined in primary esophageal and gastric carcinomas. The methylation status of the CHFR promoter region and mRNA expression in cancer cell lines were examined first. The methylation status of the CHFR gene in 38 esophageal and 53 gastric cancers was subsequently examined and the correlation between CHFR methylation and the clinicopathological findings was investigated. Aberrant methylation of the CHFR gene was detected in 9 out of 38 (24%) primary esophageal and 16 out of 53 (30%) primary gastric cancers. After methylation analysis of all the samples, the clinicopathological data were correlated with these results. There was a significant difference according to gender (p = 0.0404), indicating that female esophageal cancers were more frequently methylated than male. On the other hand, abnormal methylation was found in esophageal and gastric cancer patients at all clinical stages. Aberrant methylation of the CHFR gene was frequently shown in esophageal and gastric cancers. In addition, abnormal methylation was found in these cancer patients at all clinical stages, suggesting that this cancer could be methylated at an early stage.
- 11 July 2006
- Vol. 26, 2029-32
TAOS1, a novel marker for advanced esophageal squamous cell carcinoma.
TAOS1 (tumor amplified and overexpressed sequence 1) was recently cloned and found to be possibly important in driving the amplification of 11q13 in oral squamous cell carcinoma (SCC). Quantitative RT-PCR was performed to determine the possible relationship between TAOS1 gene expression levels and clinicopathological features in esophageal SCC. TAOS1 overexpression was observed in 7 out of 38 (18%) esophageal SCCs and CCND1 overexpression was observed in 4 out of 38 (11%), suggesting that TAOS1 was more frequently overexpressed than CCND1 in esophageal SCC. The examination of the correlation of TAOS1 overexpression with the clinicopathological features revealed a significant difference in lymph node metastasis (p = 0.014) and a trend towards advanced TNM stages (p = 0.074). The present results suggest that TAOS1 might serve as a new marker for predicting the malignancy of esophageal SCC.
- 11 July 2006
- Vol. 26, 2029-32
TAOS1, a novel marker for advanced esophageal squamous cell carcinoma.
TAOS1 (tumor amplified and overexpressed sequence 1) was recently cloned and found to be possibly important in driving the amplification of 11q13 in oral squamous cell carcinoma (SCC). Quantitative RT-PCR was performed to determine the possible relationship between TAOS1 gene expression levels and clinicopathological features in esophageal SCC. TAOS1 overexpression was observed in 7 out of 38 (18%) esophageal SCCs and CCND1 overexpression was observed in 4 out of 38 (11%), suggesting that TAOS1 was more frequently overexpressed than CCND1 in esophageal SCC. The examination of the correlation of TAOS1 overexpression with the clinicopathological features revealed a significant difference in lymph node metastasis (p = 0.014) and a trend towards advanced TNM stages (p = 0.074). The present results suggest that TAOS1 might serve as a new marker for predicting the malignancy of esophageal SCC.
- 1 January 2006
- Published by The Japanese Journal of Gastroenterological Surgery in The Japanese Journal of Gastroenterological Surgery
- Vol. 39 (11) , 1649-1657
Plasmionogen Activator Inhibitor-1 as a Potential Marker for the Malignancy of Digestive Tract Cancer
- 1 January 2006
- Published by The Japanese Journal of Gastroenterological Surgery in The Japanese Journal of Gastroenterological Surgery
- Vol. 39 (11) , 1649-1657
Plasmionogen Activator Inhibitor-1 as a Potential Marker for the Malignancy of Digestive Tract Cancer